CRL NYSE Life Sciences Tools & Services Financials FY2016βFY2025
Charles River Laboratories had $4.0B of revenue in fiscal 2025, down 0.9% on the year before. Over five years, revenue changed +6.6% a year on average.
Hi! I read Charles River Laboratoriesβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β0.9%
No. Sales fell 0.9% last year.
Does it make a profit?
β3.6%
No. It lost money last year.
Does profit turn into cash?
12.9%
Yes. 12.9% of sales ends up as free cash.
Is debt under control?
4.5x
Heavy. Repaying its debt would take 4.5 years of operating profit.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA summarises the numbers
Charles River Laboratories had $4.0B of revenue in fiscal 2025, down 0.9% on the year before.
Over five years, revenue changed +6.6% a year on average.
Its operating margin was 0.6%, down 5.0Β pts: of every 100 in sales, about 1 is left after running the business.
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Loss periods are shown in red.
KIRA summarises the numbers
Charles River Laboratories lost $144M in fiscal 2025.
Net income
Net income
Diluted EPS
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
KIRA summarises the numbers
Free cash flow was $518M in fiscal 2025, 12.9% of revenue.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
KIRA summarises the numbers
Charles River Laboratories returned $361M to shareholders in fiscal 2025, 70% of free cash flow.
The diluted share count fell 4.0%.
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
In the last 12 months, insiders bought $0.0M and sold $52.1M of shares on the open market.
Bought, 12 months
$0.0M
2 insiders
Sold, 12 months
$52.1M
6 insiders
Of sales under plans
94%
$49.1M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 22, 2026 | James C FosterDirector | Sold plan | 24,042 | $350.00 | $8.4M | Form 4 |
| Oct 21, 2026 | Shannon M ParisottoCEVP, Disc & Safety Assessment | Sold plan | 2,156 | $344.41 | $0.7M | Form 4 |
| Oct 5, 2026 | Shannon M ParisottoCEVP, Disc & Safety Assessment | Sold plan | 981 | $308.44 | $0.3M | Form 4 |
| Sep 30, 2026 | Glenn ColemanEVP & Chief Financial Officer | Bought | 10 | $297.43 | $0.0M | Form 4 |
| Aug 25, 2026 | James C FosterDirector | Sold plan | 33,561 | $300.00 | $10.1M | Form 4 |
| Aug 19, 2026 | Shannon M ParisottoCEVP, Disc & Safety Assessment | Sold plan | 2,039 | $294.12 | $0.6M | Form 4 |
| Aug 18, 2026 | Nancy C AndrewsDirector | Sold | 573 | $285.24 | $0.2M | Form 4 |
| Aug 11, 2026 | Birgit GirshickChief Executive Officer, Director | Sold plan | 6,500 | $279.90 | $1.8M | Form 4 |
| Aug 11, 2026 | Shannon M ParisottoCEVP, Disc & Safety Assessment | Sold plan | 3,714 | $279.66 | $1.0M | Form 4 |
| Aug 10, 2026 | James C FosterDirector | Sold plan | 28,733 | $275.00 | $7.9M | Form 4 |
| Aug 6, 2026 | Michael Gunnar KnellSVP, Finance and CAO | Sold | 6,645 | $260.38 | $1.7M | Form 4 |
| Aug 6, 2026 | Victoria L CreamerEVP & Chief People Officer | Sold | 4,179 | $259.16 | $1.1M | Form 4 |
| Aug 5, 2026 | Shannon M ParisottoCEVP, Disc & Safety Assessment | Sold plan | 5,046 | $263.00 | $1.3M | Form 4 |
| Jun 29, 2026 | James C FosterDirector | Sold plan | 75,000 | $225.00 | $16.9M | Form 4 |
| Mar 3, 2026 | Joseph W LaPlumeEVP, Corp Strategy & Develop | Bought | 25 | $174.54 | $0.0M | Form 4 |
| Aug 22, 2025 | Joseph W LaPlumeEVP, Corp Strategy & Develop | Sold | 400 | $163.72 | $0.1M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Charles River Laboratories can carry it.
KIRA summarises the numbers
Charles River Laboratories owes $1.9B more than it holds in cash, about 4.5 years of operating profit.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $242M | $234M | $277M | $195M | $214M |
| Debt incl. finance leases | $2.7B | $2.7B | $2.7B | $2.2B | $2.1B |
| Net debt / EBITDA | 2.8x | 2.6x | 2.6x | 3.5x | 4.5x |
| Debt / equity | 1.1x | 0.9x | 0.7x | 0.7x | 0.7x |
| Interest coverage | 8.0x | 11.0x | 4.5x | 1.8x | 0.2x |
| Current ratio | 1.2x | 1.3x | 1.5x | 1.4x | 1.3x |
| Quick ratio | 1.0x | 1.1x | 1.2x | 1.1x | 1.0x |
| Total assets | $7.0B | $7.6B | $8.2B | $7.5B | $7.1B |
| Total liabilities | $4.4B | $4.6B | $4.5B | $4.0B | $3.9B |
| Shareholders' equity | $2.5B | $3.0B | $3.6B | $3.5B | $3.2B |
| Net debt (β = net cash) | $2.4B | $2.5B | $2.4B | $2.0B | $1.9B |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
KIRA summarises the numbers
Its return on capital was 0.4%: every 100 invested in the business earned about 0 in a year.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
KIRA summarises the numbers
Charles River Laboratories passes 4 of 8 financial health tests (Piotroski F-score).
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 5 / 8 | 4 / 8 | 4 / 8 |
| Accruals ratio | β2.7% | β9.1% | β12.0% |
| Altman Z'' | 2.53 | 2.25 | 1.81 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
What does the share cost, and how does it compare?
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
KIRA summarises the numbers
At $357.27 a share, the company is worth $17.1B.
Value per share
β
Adds net cash of β$1.9B and divides by 49.6M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
KIRA summarises the numbers
Charles River Laboratories grew sales faster than 0 of its 4 similar companies.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Charles River Laboratories CRL | $17.1B | β0.9% | 0.6% | 12.9% | 0.4% | β | 4 | |
| Mettler Toledo MTD | $33.7B | 4.0% | β | 21.1% | 50.5% | 37.6x | 7 | Compare β |
| Illumina ILMN | $41.5B | β0.7% | 18.6% | 21.4% | 20.3% | 50.6x | 8 | Compare β |
| Waters WAT | $44.8B | 7.0% | 25.4% | 17.1% | 21.0% | β | 6 | Compare β |
| Bio-Rad Laboratories BIO | $10.0B | 0.7% | 1.8% | 14.5% | 0.5% | 46.6x | 5 | Compare β |
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.7B | $1.9B | $2.3B | $2.6B | $2.9B | $3.5B | $4.0B | $4.1B | $4.1B | $4.0B |
| Gross profit | $1.4B | $1.6B | β | β | β | β | β | β | β | β |
| Operating income | $238M | $288M | $331M | $351M | $433M | $590M | $651M | $617M | $227M | $25.2M |
| Interest expense | $27.7M | $29.8M | $63.8M | $60.9M | $86.4M | $73.9M | $59.3M | $137M | $126M | $107M |
| Pretax income | $223M | $297M | $282M | $304M | $447M | $481M | $623M | $581M | $93.1M | β$99.5M |
| Income tax | $66.8M | $171M | $54.5M | $50.0M | $81.8M | $81.9M | $130M | $101M | $67.8M | $42.7M |
| Net income | $155M | $123M | $226M | $252M | $364M | $391M | $486M | $475M | $22.2M | β$144M |
| Diluted EPS | $3.23 | $2.54 | $4.62 | $5.07 | $7.20 | $7.60 | $9.48 | $9.22 | $0.20 | β$2.91 |
| Diluted shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| Cash flow | ||||||||||
| Cash from operations | $317M | $318M | $441M | $481M | $547M | $761M | $620M | $684M | $735M | $738M |
| Capital expenditure | $55.3M | $82.4M | $140M | $141M | $167M | $229M | $325M | $319M | $233M | $219M |
| Free cash flow | $262M | $236M | $301M | $340M | $380M | $532M | $295M | $365M | $502M | $518M |
| Depreciation and amortization | $127M | $131M | $162M | $198M | $235M | $266M | $304M | $314M | $362M | $403M |
| Stock-based compensation | $43.6M | $44.0M | $47.3M | $57.3M | $56.3M | $71.5M | $73.6M | $72.0M | $69.9M | $71.1M |
| Acquisitions | $649M | $25.0M | $825M | $516M | $419M | $1.3B | $283M | $195M | $5.5M | $0.0M |
| Share buybacks | $12.3M | $107M | $13.8M | $18.1M | $24.0M | $40.7M | $38.7M | $24.2M | $119M | $361M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $12.3M | $107M | $13.9M | $18.1M | $24.0M | $40.7M | $38.7M | $24.2M | $119M | $361M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $121M | $192M | $196M | $239M | $229M | $242M | $234M | $277M | $195M | $214M |
| Total debt | $1.2B | $1.1B | $1.6B | $1.9B | $2.0B | $2.7B | $2.7B | $2.7B | $2.2B | $2.1B |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $30.5M | $29.0M | $27.2M | $30.6M | $28.5M | $28.4M | $27.9M |
| Current assets | $657M | $827M | $898M | $1.0B | $1.2B | $1.3B | $1.4B | $1.6B | $1.4B | $1.4B |
| Current liabilities | $430M | $464M | $558M | $710M | $840M | $1.0B | $1.1B | $1.1B | $994M | $1.1B |
| Inventory | $95.8M | $115M | $128M | $161M | $186M | $199M | $256M | $380M | $279M | $299M |
| Property and equipment, net | $756M | $782M | $933M | $1.0B | $1.1B | $1.3B | $1.5B | $1.6B | $1.6B | $1.7B |
| Total assets | $2.7B | $2.9B | $3.9B | $4.7B | $5.5B | $7.0B | $7.6B | $8.2B | $7.5B | $7.1B |
| Total liabilities | $1.9B | $1.9B | $2.5B | $3.0B | $3.3B | $4.4B | $4.6B | $4.5B | $4.0B | $3.9B |
| Shareholders' equity | $837M | $1.0B | $1.3B | $1.6B | $2.1B | $2.5B | $3.0B | $3.6B | $3.5B | $3.2B |
| Margins | ||||||||||
| Gross margin | 83.5% | 84.4% | β | β | β | β | β | β | β | β |
| Operating margin | 14.1% | 15.5% | 14.6% | 13.4% | 14.8% | 16.7% | 16.4% | 15.0% | 5.6% | 0.6% |
| EBITDA margin | 21.7% | 22.6% | 21.8% | 21.0% | 22.8% | 24.2% | 24.0% | 22.6% | 14.6% | 10.7% |
| Net margin | 9.2% | 6.6% | 10.0% | 9.6% | 12.5% | 11.0% | 12.2% | 11.5% | 0.6% | β3.6% |
| FCF margin | 15.6% | 12.7% | 13.3% | 13.0% | 13.0% | 15.0% | 7.4% | 8.9% | 12.4% | 12.9% |
| Returns | ||||||||||
| Return on capital | 10.1% | 7.5% | 11.4% | 9.8% | 9.9% | 11.1% | 9.9% | 8.9% | 2.0% | 0.4% |
| Return on capital employed | 11.8% | 12.1% | 11.5% | 9.7% | 10.0% | 11.1% | 10.4% | 9.0% | 3.3% | 0.4% |
| Return on equity | 19.7% | 13.1% | 19.2% | 17.1% | 19.4% | 16.8% | 17.7% | 14.4% | 0.6% | β4.4% |
| Return on assets | 6.5% | 4.4% | 6.7% | 5.9% | 7.2% | 6.3% | 6.7% | 6.0% | 0.3% | β2.0% |
| Growth | ||||||||||
| Revenue growth | 23.3% | 10.5% | 22.0% | 15.7% | 11.6% | 21.1% | 12.3% | 3.9% | β1.9% | β0.9% |
| Net income growth | 3.7% | β20.3% | 83.5% | 11.3% | 44.6% | 7.3% | 24.4% | β2.4% | β95.3% | β750.1% |
| EPS growth | 3.2% | β21.4% | 81.9% | 9.7% | 42.0% | 5.6% | 24.7% | β2.7% | β97.8% | β1,555.0% |
| FCF growth | 7.4% | β9.9% | 27.8% | 13.1% | 11.6% | 40.0% | β44.6% | 23.9% | 37.3% | 3.4% |
| Share count change | 0.7% | 1.3% | 0.9% | 1.4% | 1.9% | 1.6% | β0.2% | 0.3% | 0.3% | β4.0% |
| Financial health | ||||||||||
| Net debt / EBITDA | 2.9x | 2.1x | 2.9x | 3.0x | 2.6x | 2.8x | 2.6x | 2.6x | 3.5x | 4.5x |
| Debt / equity | 1.4x | 1.0x | 1.2x | 1.2x | 0.9x | 1.1x | 0.9x | 0.7x | 0.7x | 0.7x |
| Interest coverage | 8.6x | 9.7x | 5.2x | 5.8x | 5.0x | 8.0x | 11.0x | 4.5x | 1.8x | 0.2x |
| Current ratio | 1.5x | 1.8x | 1.6x | 1.4x | 1.4x | 1.2x | 1.3x | 1.5x | 1.4x | 1.3x |
| Quick ratio | 1.3x | 1.5x | 1.4x | 1.2x | 1.2x | 1.0x | 1.1x | 1.2x | 1.1x | 1.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.3% | 4.4% | 6.2% | 5.4% | 5.7% | 6.5% | 8.2% | 7.7% | 5.8% | 5.5% |
| Stock comp / revenue | 2.6% | 2.4% | 2.1% | 2.2% | 1.9% | 2.0% | 1.9% | 1.7% | 1.7% | 1.8% |
| Payouts / FCF | 4.7% | 45.4% | 4.6% | 5.3% | 6.3% | 7.7% | 13.1% | 6.6% | 23.8% | 69.6% |
| Quality scores | ||||||||||
| Piotroski F-score | 5.0 | 6.0 | 5.0 | 4.0 | 5.0 | 4.0 | 6.0 | 5.0 | 4.0 | 4.0 |
| Altman Z'' | 1.8 | 2.4 | 1.7 | 1.7 | 2.0 | 1.9 | 2.2 | 2.5 | 2.3 | 1.8 |
| Accruals ratio | β6.8% | β6.9% | β6.3% | β5.4% | β3.6% | β5.9% | β1.8% | β2.7% | β9.1% | β12.0% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001100682). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
